Molecular structure of PETCM, CAS Number: 10129-56-3
PETCM (CAS 10129-56-3)
Application:
PETCM is a caspace-3 activator in cell extracts
CAS Number:
10129-56-3
Purity:
≥95%
Molecular Weight:
240.5
Molecular Formula:
C8H8Cl3NO
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
PETCM is an activator of caspase-3 and a stimulator of apoptosome formation in HeLa cell cytosols. In addition, studies suggest that PETCM can reverse the inhibitory effects of putative HLA-DR-associated proteins (PHAP) on caspase-3 activation. Since caspase-3 activation is dependent on apoptosome formation, prothymosin alpha can inhibit the activation of caspase-3 by disrupting the formation of the apoptosome somewhere upstream in this regulatory pathway. Studies suggest that PETCM can eliminate the inhibitory effects of prothymosin alpha by acting as an antagonist and allwing PHAP to stimulate apoptosome formation at a physiological concentration of deoxyadenosine triphosphate.
PETCM (CAS 10129-56-3) References
- Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. | Jiang, X., et al. 2003. Science. 299: 223-6. PMID: 12522243
- Direct activation of the apoptosis machinery as a mechanism to target cancer cells. | Nguyen, JT. and Wells, JA. 2003. Proc Natl Acad Sci U S A. 100: 7533-8. PMID: 12808146
- Chemical-induced apoptosis: formation of the Apaf-1 apoptosome. | Cain, K. 2003. Drug Metab Rev. 35: 337-63. PMID: 14705865
- Apoptosis-like cell death of human breast cancer cell line MCF-7 induced by buprenorphine hydrochloride. | Kugawa, F., et al. 2004. Life Sci. 75: 287-99. PMID: 15135650
- Defects of the apoptotic pathway as therapeutic target against cancer. | Mashima, T. and Tsuruo, T. 2005. Drug Resist Updat. 8: 339-43. PMID: 16338161
- Modulation of cellular apoptosis with apoptotic protease-activating factor 1 (Apaf-1) inhibitors. | Mondragón, L., et al. 2008. J Med Chem. 51: 521-9. PMID: 18197610
- Novel small molecules relieve prothymosin alpha-mediated inhibition of apoptosome formation by blocking its interaction with Apaf-1. | Qi, X., et al. 2010. Biochemistry. 49: 1923-30. PMID: 20121050
- Differential immunotoxicity of histone deacetylase inhibitors on malignant and naïve hepatocytes. | Weiller, M., et al. 2011. Exp Toxicol Pathol. 63: 511-7. PMID: 20537879
- Intracellular and extracellular cytokine-like functions of prothymosin α: implications for the development of immunotherapies. | Mosoian, A. 2011. Future Med Chem. 3: 1199-208. PMID: 21806381
- [The role of the apoptosome in the activation of procaspase-9]. | Marek, Ł. 2013. Postepy Hig Med Dosw (Online). 67: 54-64. PMID: 23475483
- Biological evaluation of octahydropyrazin[2,1-a:5,4-a']diisoquinoline derivatives as potent anticancer agents. | Gornowicz, A., et al. 2017. Tumour Biol. 39: 1010428317701641. PMID: 28618951
- Loss of Non-Apoptotic Role of Caspase-3 in the PINK1 Mouse Model of Parkinson's Disease. | Imbriani, P., et al. 2019. Int J Mol Sci. 20: PMID: 31336695
- Cell Death Related Proteins Beyond Apoptosis in the CNS. | Bahatyrevich-Kharitonik, B., et al. 2021. Front Cell Dev Biol. 9: 825747. PMID: 35096845
- FGF13-Sensitive Alteration of Parkin Safeguards Mitochondrial Homeostasis in Endothelium of Diabetic Nephropathy. | Sun, J., et al. 2023. Diabetes. 72: 97-111. PMID: 36256844
Activator of:
caspase-3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PETCM, 10 mg | sc-202279 | 10 mg | $32.00 | |||
PETCM, 50 mg | sc-202279A | 50 mg | $86.00 |